Richard B Bell (R Bryan Bell, R Bryan Bell, Richard Bryan Bell)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Squamous Cell Carcinoma

Regulatory T Cells

Monoclonal Antibody

Top Venues

Cancer immunology research

Nature communications

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
Rom S Leidner, Marka Crittenden, Kristina Young, Hong Xiao, Yaping Wu, Marcus A Couey, Ashish A Patel, Allen C Cheng, Amber L Watters, Carlo Bifulco, George Morris, Lessli Rushforth, Shorin Nemeth, Walter J Urba, Michael J Gough, Richard B Bell
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. Journal for immunotherapy of cancer 9 (5) (2022)
Charles W Drescher, Adam J Bograd, Shu-Ching Chang, Roshanthi K Weerasinghe, Ann Vita, Richard B Bell
Cancer case trends following the onset of the COVID-19 pandemic: A community-based observational study with extended follow-up. Cancer 128 (7) (2021)
Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K Frye, Eric Tran, Venkatesh Rajamanickam, Shu-Ching Chang, Yoshinobu Koguchi, Carlo B Bifulco, Brady Bernard, Rom S Leidner, Brendan D Curti, Bernard A Fox, Walter J Urba, Richard B Bell, Andrew D Weinberg
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nature communications 12 (1) (2021)
Matthew J Ferris, Yael Flamand, Gregory S Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J Garcia, Christine H Chung, Maura L Gillison, Umamaheswar Duvvuri, Bert W O'Malley, Enver Ozer, Giovana R Thomas, Wayne M Koch, Neil D Gross, Richard B Bell, Nabil F Saba, Miriam N Lango, Eduardo Méndez, Barbara A Burtness
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Hongjun Li, Ze-Jun Wang, Zhaowei Chen, Tianyuan Ci, Guojun Chen, Di Wen, Ruoxin Li, Jinqiang Wang, Huan Meng, Richard B Bell, Zhi-Feng Gu, Gianpietro Dotti, Zhen Gu
Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis. Nature communications 12 (1) (2021)
Lauren Hum, Daniel Bethmann, Zipei Feng, Shu-Ching Chang, Alexander Eckert, Carmen Ballesteros-Merino, Claudia Keschke, Matthias Kappler, Carlo B Bifulco, Claudia Wickenhauser, Barbara Seliger, Bernard A Fox, Richard B Bell
Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus-negative oral squamous cell carcinomas with negative resection margins. Head & neck 43 (2) (2020)